SCHEMBL17286111

SCHEMBL17286111

CC(C)[C@H](NC(=O)Nc1ccc(Br)cc1)c1ncc[nH]1

nearest known ligand 1.00 ✓ in ChEMBL — recovers established targets

Predicted protein targets (top 9)

geneUniProtsupporting neighboursconfidence
FPR2 P25090 17/20 1.00
MEN1 O00255 1/20 0.52
LMNA P02545 1/20 0.52
POLB P06746 1/20 0.52
KMT2A Q03164 1/20 0.52
SMN1; SMN2 Q16637 1/20 0.52
FPR1 P21462 1/20 0.52
RAB9A P51151 1/20 0.49
CNR1 P21554 1/20 0.46

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL21698107 1.00 FPR2 (1.00) FPR2MEN1LMNAPOLBKMT2A
SCHEMBL17286118 0.88 FPR2 (1.00) FPR2MEN1KMT2ARAB9ACNR1
SCHEMBL21669963 0.88 FPR2 (1.00) FPR2MEN1KMT2ARAB9ACNR1
SCHEMBL17286119 0.87 FPR2 (1.00) FPR2MEN1LMNAPOLBKMT2A
SCHEMBL21669954 0.85 FPR2 (1.00) FPR2MEN1POLBKMT2ASMN1; SMN2
SCHEMBL17286120 0.85 FPR2 (1.00) FPR2MEN1POLBKMT2ASMN1; SMN2
SCHEMBL21669951 0.84 FPR2 (1.00) FPR2
SCHEMBL17286117 0.84 FPR2 (1.00) FPR2
SCHEMBL17286115 0.82 FPR2 (1.00) FPR2LMNAKMT2ASMN1; SMN2RAB9A
SCHEMBL21669955 0.82 FPR2 (1.00) FPR2LMNAKMT2ASMN1; SMN2RAB9A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-10800744-B2 Imidazole derivatives as formyl peptide receptor modulators ALLERGAN, INC. (US) 2020-10-13 US disclosed
US-10800744-B2 Imidazole derivatives as formyl peptide receptor modulators ALLERGAN, INC. (US) 2020-10-13 US disclosed
US-20200115346-A1 IMIDAZOLE DERIVATIVES AS FORMYL PEPTIDE RECEPTOR MODULATORS ALLERGAN INC (US) 2020-04-16 US disclosed
EP-3145916-B1 IMIDAZOLE DERIVATIVES AS FORMYL PEPTIDE RECEPTOR MODULATORS ALLERGAN INC (US) 2020-02-12 EP disclosed
EP-3145916-B1 IMIDAZOLE DERIVATIVES AS FORMYL PEPTIDE RECEPTOR MODULATORS ALLERGAN INC (US) 2020-02-12 EP disclosed
US-10301269-B2 Imidazole derivatives as formyl peptide receptor modulators ALLERGAN, INC. (US) 2019-05-28 US disclosed
US-10301269-B2 Imidazole derivatives as formyl peptide receptor modulators ALLERGAN, INC. (US) 2019-05-28 US disclosed
US-20170096401-A1 IMIDAZOLE DERIVATIVES AS FORMYL PEPTIDE RECEPTOR MODULATORS ALLERGAN, INC. 2017-04-06 US disclosed
US-20170096401-A1 IMIDAZOLE DERIVATIVES AS FORMYL PEPTIDE RECEPTOR MODULATORS ALLERGAN, INC. 2017-04-06 US disclosed
WO-2015179707-A1 IMIDAZOLE DERIVATIVES AS FORMYL PEPTIDE RECEPTOR MODULATORS ALLERGAN, INC. (US) 2015-11-26 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20200115346-A1 IMIDAZOLE DERIVATIVES AS FORMYL PEPTIDE RECEPTOR MODULATORS FPR1, FPR3, FPR2 FPR2 3/4885MEN1 2983/4885LMNA 4222/4885
US-20170096401-A1 IMIDAZOLE DERIVATIVES AS FORMYL PEPTIDE RECEPTOR MODULATORS FPR1, FPR3, FPR2 FPR2 3/4885MEN1 2983/4885LMNA 4222/4885
US-10301269-B2 Imidazole derivatives as formyl peptide receptor modulators FPR1, FPR3, FPR2 FPR2 3/4885MEN1 2983/4885LMNA 4222/4885
US-10800744-B2 Imidazole derivatives as formyl peptide receptor modulators FPR1, FPR3, FPR2 FPR2 3/4885MEN1 2983/4885LMNA 4222/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.